Premium
J anus kinase Inhibition and its effect upon the therapeutic landscape for myelofibrosis: from palliation to cure?
Author(s) -
Harrison Claire,
Verstovsek Srdan,
McMullin Mary F.,
Mesa Ruben
Publication year - 2012
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.2012.09108.x
Subject(s) - myelofibrosis , medicine , janus kinase , anus , myeloproliferative disorders , mutation , oncology , intensive care medicine , cancer research , bioinformatics , surgery , biology , genetics , bone marrow , receptor , gene
Summary Following the discovery of the J anus kinase ( JAK ) 2 V 617 F mutation in 2005 the explosion of research and drug development activity has not only advanced our understanding of the pathogenesis of myeloproliferative neoplasms ( MPN s) but also triggered debate about classification, allowed revised diagnostic and response criteria, provided a target for treatment and a mode of monitoring its success. These changes and the resultant clinical research are discussed in this article where we argue that discovery of the JAK 2 V 617 F mutation has signalled the much delayed change in therapeutic paradigm for myelofibrosis and possibly other MPN s from palliation and allowing us to move closer to, but not yet attain, a cure.